Treatment with v‐Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors and mitogen‐activated protein kinase (MEK) inhibitors can induce rapid tumor control with improved overall survival (OS) in BRAF mutant melanoma patients; however, the duration of response is often short lived.1, 2. This evidence concerns the gene BRAF and neoplasm.